| Literature DB >> 28534010 |
Soo-Young Oh1, Cheong-Rae Roh1.
Abstract
Autophagy is an evolutionarily conserved catalytic process by which cytoplasmic components including damaged macromolecules and organelles are degraded. The role of autophagy includes adaptive responses to nutrition deprivation or intracellular stimuli. Although autophagosomes were first observed in early 1960s, it was 1990s that autophagy-related genes in yeast were identified and studied. Nowadays, the molecular machinery of autophagy and signaling pathway to various stimuli are almost outlined. Dysregulation of autophagic activity has been implicated in many human diseases including neurodegenerative diseases, infection and inflammation, and malignancies. However, since current understanding of autophagy in placenta is just at the beginning, this paper aims to provide general information on autophagy (part I) and to summarize articles on autophagy in human placenta (part II). This review article will serve as a basis for further researches on autophagy in relation to human pregnancy and its complications.Entities:
Keywords: Autophagy; Placenta; Trophoblasts
Year: 2017 PMID: 28534010 PMCID: PMC5439273 DOI: 10.5468/ogs.2017.60.3.241
Source DB: PubMed Journal: Obstet Gynecol Sci ISSN: 2287-8572
Fig. 1Steps in autophagy process. Autophagy begins with the formation of an isolation membrane (phagophore), which elongates into an autophagosome. The mature autophagosome engulfs intracellular cargo such as mitochondria, protein aggregate, and lipid droplet and also microorganisms invaded to the host cells. The mature autophagosome fused with lysosome and formed into autophagolysosome, where autophagolysosomal cargos are degraded by lysosomal protease.
Summaries of studies on autophagy in placenta with preeclampsia and FGR
| Author (year) | Study population | Gestational age at delivery (wk)a) | Neonatal weight (g)a) | Methods used | Markers of autophagy assessed and results compared to normal pregnancy | Conclusions |
|---|---|---|---|---|---|---|
| Oh et al. (2008) [ | Normal (n=8) | 38.6 (38.3–39.3) | 3,265 (3,010–4,220) | WB, RT-PCR, IHC | LC3-II ↑, beclin 1 (−) | Increase autophagy in severe PE |
| Hung et al. (2012) [ | Normal (n=14) | 38.3±1.0 | 3,176±567 | IF, WB, real time qPCR | LC3-II ↑, beclin 1 ↑, DRAM ↑ | Increase autophagy in FGR or FGR+PE |
| Curtis et al. (2013) [ | Normal (n=6) | 39+2 (37+6–39+5) | 3,440 (2,550–3,570) | WB, IHC | LC3-B↑, LAMP-2 (−) | Increase autophagy in FGR |
| Normal (n=6) | 40+0 (38+2–41+5) | 3,510 (2,850–4,380) | EM | Autophagic vacuole↑ | ||
| Akaishi et al. (2014) [ | Normal (n=19) | 37.0±3.0 | 2,700±600 | WB | LC3-II ↑, p62 ↓ | Increase autophagy in hypertensive disorders (gestational HT or PE) regardless of FGR |
| Gao et al. (2015) [ | Normal (n=20) | 39.0±1.2 | 2,886±609 | IHC, IF | LC3-II ↑, beclin 1 ↑ | Increase autophagy in early onset PE |
FGR, fetal growth restriction; PE, preeclampsia; WB, western blot; RT-PCR, reverse transcription polymerase chain reaction; IHC, immunohistochemistry; LC3, microtubule-associated proteins light chain 3; IF, immunofluorescence; qPCR, quantitative polymerase chain reaction; DRAM, damage-regulated autophagy modulator; NS, not significant; LAMP, lysosomal-associated membrane protein; EM, electron microscopy; HT,hypertension.
a)P-value to compare gestational age at delivery and neonatal weight between preeclampsia or FGR compared to normal pregnancy was presented in each study; b)FGR defined as <5 percentile; c)FGR defined as <3 percentile, (−), no difference.
Summaries of studies on autophagy in trophoblast cells in response to various stimuli
| Author (year) | Cells used | Inducers (or stimulants) | Time point assessed | Markers of autophagy and results (compared to control) | Remarks |
|---|---|---|---|---|---|
| Oh et al. (2008) [ | JEG3 | Hypoxic chamber (O2 <1% vs. 20%) | 12, 24, 48 hr | LC3-II (−), beclin 1 (−) | Hypoxia increased fluorescent punctuations after 24 hr |
| TNF-α (10 ng/mL) | 12, 24, 48 hr | LC3-II , beclin 1 ↓ | |||
| Chen et al. (2012) [ | Primary trophoblasts | Hypoxia (<1% vs. | 1, 2, 4, 24 hr | LC3-II ↓ (but ↑in bafilomycin co-treatment) | Increase in autophagic flux in hypoxia |
| Rapamycin | 4 hr | LC3-II ↑ (in bafilomycin co-treatment) | |||
| Hung et al. (2012) [ | Primary trophoblasts | Hypoxia (2% vs. 20%) | 48 hr | LC3-II ↑, DRAM ↑ | Increased p53 was accompanied |
| Hung et al. (2013) [ | Primary trophoblasts | Oxygen glucose deprivation (2% O2 vs. 18%, glucose free medium) | 48 hr | LC3-II ↑, beclin 1 ↓, DRAM ↓ | |
| Curtis et al. (2013) [ | BEWO | Hypoxia (6% vs. 21%) Serum deplete (5% vs. 10%) | 48 hr | Vacuolation ↑ | |
| Nakashima et al. (2013) [ | HTR8/SVneo | Hypoxia (2% vs. 20%) | 24 hr | LC3-II ↑, sequestosome1 ↓ | Starvation (by Hank's solution) also increased LC3 punctations |
| Yamanaka-Tatematsu et al. (2013) [ | HTR8/SVneo | CoCl2 | 4 hr (for WB) 24 hr (for IF) | LC3-II ↑ | |
| Melland-Smith et al. (2015) [ | JEG3 | C16 ceramides Acid ceramidase inhibitor (2-OE) | 6 hr | LC3-II ↑, sequestosome1 ↑, autophagosome ↑ | C16 ceramides increased cleaved caspase 3 in 24 h |
| Gao et al. (2015) [ | HTR8/SVneo HUVECs | Oxidative stress inducer (glucose oxidase) | 5–6 hr for HTR8/SVneo cells | LC3-II ↑, beclin 1 ↑, autophagosome ↑ | Increase autophagy by glucose oxidase was also inhibited by 3-MA |
TNF-α, tumor necrosis factor-α; LC3, microtubule-associated proteins light chain 3; DRAM, damage regulated autophagy regulator; LAMP, lysosomal-associated membrane protein; WB, western blot; IF, immunofluorescence; 2-OE, 2-oleoylethanolamine; HUVEC, human umbilical vein endothelial cell; 3-MA, 3-methyladenine; MMP-9, matrix metallopeptidase 9.